One of the most highly-cited journals in cardiology has retracted a paper less than a month after publishing it in response to criticism first posted on Twitter.
The article, “Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials,” was published online January 3 in the European Heart Journal (EHJ). Its authors purported to analyze clinical trials of patients who were given a loading dose of atorvastatin, a cholesterol medication, before undergoing cardiac catheterization.
How closely the study authors adhered to their own methods came under question on January 8, when Ricky Turgeon, a cardiology pharmacist, posted a series of tweets in which he claimed some of the studies included in the analysis either did not test the drug in patients undergoing the procedure — referred to as PCI — or patients had not all been diagnosed with acute coronary syndrome, commonly known as a heart attack. With many of the trials included in the analysis not abiding by the predefined inclusion criteria, the study’s conclusions are unreliable, argued Turgeon.Continue reading Should journals credit eagle-eyed readers by name in retraction notices?
The European Heart Journal has issued an expression of concern for a 2014 2001 paper by Don Poldermans, the Dutch heart researcher who stepped down from his post at Erasmus University after being accused of misconduct.
The article, “Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery,” appeared in July and reported data from the DECREASE trial. Poldermans, who left Erasmus in 2011, has acknowledged failing to receive informed consent from some patients in one phase of the DECREASE study but denied having fabricated results.
Just 48 hours after publishing an article by Graham Cole and Darrel Francis last week alleging that Don Poldermans‘ scientific misconduct led to the deaths of some 800,000 Europeans over the past five years by tainting clinical guidelines, the European Heart Journal unceremoniously pulled the paper from its website Friday.